CJC-1295-WITH DAC 5mg

Description

CJC-1295 with DAC – Advanced Biochemical Mechanism & Pathway Profile

(Growth Hormone–Releasing Hormone Analogue + Drug Affinity Complex)

CJC-1295 with DAC is a long-acting synthetic analogue of Growth Hormone–Releasing Hormone (GHRH1-29). The DAC (Drug Affinity Complex) enables covalent binding to serum albumin, dramatically extending plasma half-life and allowing prolonged interaction with GHRH receptors in research models.

✅ Primary Receptor Target: GHRH Receptor (GHRH-R)

• CJC-1295 binds the GHRH receptor, a Class B GPCR located primarily on somatotrophs in the anterior pituitary.

• GHRH-R coupling: Gs → adenylate cyclase → ↑ cAMP → PKA activation

• PKA activates CREB and additional transcription factors that regulate GH-related gene expression.

✅ Core Intracellular Pathways

1. cAMP / PKA / CREB Axis

• GHRH-R activation → Adenylate Cyclase ↑

• cAMP increases

• PKA phosphorylates:

  • CREB (cAMP response element–binding protein)

  • Ca²⁺ channel regulatory proteins

  • Transcriptional coactivators

Genes commonly studied:

• GH1 (growth hormone gene)

• GHRHR (autoregulatory receptor expression)

• PIT1 (POU1F1) – pituitary lineage transcription factor

2. Calcium-Dependent Secretory Pathway

• PKA enhances voltage-gated Ca²⁺ influx

• Intracellular Ca²⁺ triggers vesicular GH release from somatotroph granules

• This process is frequently analyzed in endocrine secretion models

3. MAPK / ERK Cascade

CJC-1295 exposure has been associated with:

• Ras → Raf → MEK1/2 → ERK1/2 phosphorylation

• Transcription of genes related to somatotroph proliferation and GH synthesis

✅ Prolonged Action via DAC (Drug Affinity Complex)

The DAC motif enables selective covalent binding to circulating albumin, reducing renal filtration and enzymatic degradation.

• Extends biological availability in vitro

• Provides sustained stimulation of GHRH-R signaling

• Allows long-term cAMP/CREB transcriptional activation to be studied

This makes CJC-1295 with DAC distinct from short-acting GHRH analogues such as modified GRF(1-29).

✅ Downstream Research Pathways of Interest

Although CJC-1295 does not bind GH receptors directly, prolonged GHRH-R signaling allows researchers to examine:

• Somatotroph gene transcription (PIT1, GH1)

• Vesicle-fusion machinery influenced by Ca²⁺ signaling

• cAMP/PKA-dependent endocrine gene regulation

• MAPK-mediated transcriptional programs

• Receptor desensitization and GPCR trafficking

✅ Key Molecular Targets

Research-Only Classification

CJC-1295 with DAC is provided solely for in-vitro laboratory research.
It is not approved for human or animal use, therapeutic application, or diagnostic procedures.